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Multiple factors determine the resistance of tumours
against radiation treatment (RT) and chemotherapy.
Tumours may show an intrinsic, genetically determined
inherent resistance. However, extrinsic physiological
(environmental) factors are also important. Most critical
is the presence of less or inadequate and heterogeneous
vascular networks leading to chronic ‘diffusion-limited’
tumour hypoxia. Tumour hypoxia is also an acute cyclic
phenomenon as part of a dynamic process in which the
vessels periodically open and close. The latter type is
translated as ‘perfusion-limited’ hypoxia.
There is strong evidence that for some human tumours
treatment may fail due to the presence of hypoxia [1].
Therefore, the presence of tumour hypoxia needs to
be identified and quantified, not only as predictor of
outcome, but also to select patients for concomitant
radiosensitising therapy to overcome the hypoxia effect.
Treatments such as hyperbaric oxygen or carbogen (95–
98% O2 with 2–5% CO2) breathing during RT have
been extensively investigated and initiated in clinics [2].
The adequate appreciation of tumour hypoxia may also
lead to the efficient use of hypoxia-directed treatments
such as bioreductive drugs or gene therapy. Also the
modulation of hypoxia from targeting tumour vasculature
is another area of clinical interest that can profit from such
measurements.
Direct quantification of tumour oxygenation can
thus be expected to be of important prognostic and
therapeutic value. However, until now appreciation of
tumour oxygenation needs the application of invasive
methods, such as biopsy-based immunohistochemistry
using pimonidazole, or the use of Eppendorf oxygen-
sensitive electrodes to screen tumours for hypoxia.
Tumour oxygenation as evaluated with oxygen-
sensitive needle electrodes was shown to be of prognostic
interest in certain human tumours, such as in metastatic
neck adenopathies, cervix carcinoma, sarcomas and
recurrent pelvic tumours [3]. However, oxygen-sensitive
needle electrodes can only to a certain extent be used,
as some primary tumours are deeply seated, difficult to
reach and close to critical anatomic structures.
There is a clear need for non-invasive methods to
measure tumour oxygenation. Increasingly more studies
are demonstrating that imaging methods, such as com-
puted tomography (CT) and magnetic resonance imaging
(MRI), classically used to demonstrate the anatomic posi-
tion and extent of tumours, are able to provide additional,
biological information. For example, lymph node density
on contrast-enhanced CT images reflects both tissue
perfusion and degree of contrast agent diffusion in the
tissue interstitium. Within neck adenopathies, appearing
hypodense (‘necrotic’) on routine contrast-enhanced CT-
images, hypoxic conditions are present, as measured with
oxygen-sensitive electrodes [4]; such nodal hypodensity
on CT images was the only independent predictor of
locoregional failure in patients with stage III/IV head
and neck cancer receiving RT alone or simultaneous
radiation and chemotherapy [5]. A significant lower
complete response rate to chemotherapy in patients
with advanced head and neck cancer was reported in
patients showing nodal hypodensity on CT, attributed
to a reduced functional vascularisation of such lymph
nodes for efficient drug delivery [6]. Other studies failed
to confirm nodal necrosis, as visible on CT studies, as
a prognostic factor for locoregional outcome in patients
treated with RT or neoadjuvant chemotherapy. One of the
explanations for these conflicting results may be that pure
morphological parameters do not correlate sufficiently
with impaired vascularisation and hypoxia.
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Intuitively, one expects an inverse relationship between
maximum tumour diameter and tumour oxygenation:
larger cancers show a progressive rarefaction of the
vascular bed, structural and functional abnormalities of
the tumour microcirculation and development of necrosis.
Tumour volume can be quantified using routine cross-
sectional imaging studies; such radiologically determined
tumour volume is significantly related to local outcome,
as has been demonstrated for several head and neck
cancer sites and uterine cervical cancer. Compared to
biological predictive assays as doubling time (Tpot)
and surviving fraction (SF2), tumour volume allows a
much more precise prediction of response to RT [7].
Presumably, the prognostic value of tumour volume
is not only determined by its possible correlation to
tumour oxygenation, but also by the more or less linear
relationship between tumour volume and number of
clonogenic cells: success in controlling a tumour depends
on killing all clonogenic cells.
Another approach to estimate tumour hypoxia seems
to be feasible with ‘dynamic’ contrast-enhanced imaging
techniques; such methodology allows a combined estima-
tion of tissue perfusion, blood volume and permeability
of vessels. A relationship between dynamic contrast-
enhanced MRI parameters and tumour oxygenation has
for example been shown in cervical carcinoma, using
polarographic needle electrodes as reference [8].
Several other approaches to measuring tumour oxy-
genation are available with MRI. Tumour oxygenation
can be measured indirectly with Phosphorus-31 MR
spectroscopy. Experiments have been done using Fluor-
19-MR spectroscopy, by using perfluorocarbon com-
pounds as oxygen sensor [9], but these perfluorocarbon
compounds are currently not available for clinical use.
Another possibility is to use hydrogen-MRI, to test the
reoxygenation of a particular tumour while the patient
is breathing carbogen, using the principle of fMRI.
The blood oxygenation level-dependent (BOLD) contrast
depends on the endogenous switch from paramagnetic
deoxyhemoglobine to diamagnetic oxyhemoglobin, a
conversion that is translated in changes of MR signals.
This principle is extensively used in functional MRI
to assess brain activity triggered with exercise or
other external stimuli. Typically, tumour oxygenation
data are collected using a single-slice gradient-recalled
echo (GRE) technique at very high field strength [10].
Recently, the feasibility of using BOLD-fMRI with
echo planar imaging (EPI) in a 1.5 T clinical MR
scanner, allowing evaluation of the entire tumour volume,
was demonstrated in a rat rhabdomyosarcoma tumour
model [11]. In this study, a large intertumour variability
as well as an important intratumour difference in
response, both when the rats breathed air or carbogen,
was observed. Whereas in the majority of tumours
the signal intensity increases were positive (indicating
improved oxygenation), a negative change in signal
intensity (indicating reduced oxygenation) was seen both
in separate as well as in the same tumours. Such a
heterogeneous response to carbogen breathing was also
observed in a recent clinical study, where the principle
of BOLD-fMRI was applied to patients with head and
neck cancer [12]. In this perspective of heterogeneity, the
possibility to analyse the whole tumour in a short time is
an attractive (and even necessary) feature to quantitate the
variable effects of oxygenation modifying compounds.
With the continuous improvement of MRI hardware
and software, the development of new contrast agents
and more refined methods of image data analysis, further
progress in this field of acquiring non-invasively biologic
information on tumours can only be anticipated.
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